最新ニュース Globe Life (NYSE:GL) 株価情報

Globe Life

Globe Life Inc is an insurance holding company. It provides a variety of life and supplemental health insurance products and annuities to a broad base of customers. The company's core operations are organized into four reportable segments: life insurance, supplemental health insurance, annuities, and investments. Investment activities, conducted by the investment segment, focus on seeking investments with a yield and term appropriate to support the insurance product obligations. These investments generally consist of fixed maturities and, over the long term, the expected yields are considered when setting insurance premium rates and product profitability expectations.

Globe Life Inc

GEMINA LABORATORIES LTD by GEMINA LABORATORIES LTD.

Gemina Laboratories Ltd

Global Lights Acquisition Corp - Ordinary Shares

Global Lights Acquisition Corp

Global Lights Acquisition Corp - Rights

Gladstone Capital Corporation - Closed End Fund

Gladstone Capital Corp

Gladstone Capital Corporation - 7.75% Notes due 2028

GLASSBRIDGE ENTRPRS by GlassBridge Enterprises, Inc.

GlassBridge Enterprises Inc

Global AI Inc

GALA INC by Gala Inc.

Glanbia PLC

GLADIATOR RESOURCES LTD by GLADIATOR RESOURCES LTD

Gladiator Resources Ltd

GLASS HOUSE BRANDS INC by Glass House Brands Inc.

Glass House Brands Inc

GLOBAL ATOMIC CORP by Global Atomic Corp.

Global Atomic Corp

GSK PLC

Global Quest Ltd

Global E Online Ltd

GLOBRANDS GROUP LTD by Globrands Group Ltd.

Globrands Group Ltd

GLOBALTECH HLDGS INC by Globaltech Holdings, Inc.

Globaltech Holdings Inc

GLOBAL INVTS LTD by GLOBAL INVTS LTD.

GOLDBANK MINING CORP by Goldbank Mining Corp.

Goldbank Mining Corp

Pacer Funds Trust Pacer MSCI World Industry Advantage ETF

GLOBAL BROKERAGE INC A by Global Brokerage, Inc.

Global Brokerage Inc

GLOBAL BRANDS GROUP NEW by Global Brands Group Holding Ltd.

Globus Maritime Ltd

GLOBEX MNG ENTERPRS NEW by Globex Mining Enterprises Inc.

Globex Mining Enterprises Inc

Glen Burnie Bancorp

Goldcoin

GOOD LIFE CHINA CORP by Good Life China Corp.

Good Life China Corp

GL Events

Glitch

Glencore PLC

Global Links Corp

GLOBAL LEADERS CORP by GLOBAL LEADERS CORP

Global Leaders Corp

SPDR Gold Trust

GlobalData PLC

Great Lakes Dredge & Dock Corporation - Common Stock

Great Lakes Dredge & Dock Corp

GoldMining Inc

ETRACS Gold Shares Covered Call ETNs due February 2, 2033

SPDR Gold MiniShares Trust

GOLDEN RAPTURE MNG CORP by GOLDEN RAPTURE MNG CORP.

Global X Funds LOBAL X GOLD EXPLORERS ETF NEW

Global Engine Group Holding Limited - Ordinary Shares

Global Engine Group Holding Ltd

GLOBAL ECOLOGY CORP by Global Ecology Corp.

Global Ecology Corp

GALAXY ENTERPRISES INC WY by GALAXY ENTERPRISES INC.

Galaxy Enterprises Inc

GOLF AND CO by Golf And Co.

Gold Flora Corp

Gold Flora Corp Warrants (15/01/2026)

GLOBAL FASHION GROUP by GLOBAL FASHION GROUP SA

Global Fashion Group SA

Galenfeha Inc

New Green Hemp Inc

MCHENRY METALS GOLF CORP by McHenry Metals Golf Corp.

McHenry Metals Golf Corp

GOGOLD RESOURCES INC ORD by GoGold Resources, Inc.

GoGold Resources Inc

GREYSTONE LOGISTICS INC by Greystone Logistics, Inc.

Greystone Logistics Inc

GLG LIFE TECH CORP by GLG Life Tech Corp.

GLG Life Tech Corp

PSH GROUP HLDG INC by PSH GROUP HLDG INC.

PSH Group Holdings Inc

GREEN LEADER HLDGS GROUP by GREEN LEADER HLDGS GROUP LTD.

Green Leader Holdings Group Ltd

GOLDEN HARP RES INC NEW by Golden Harp Resources Inc.

Golden Harp Resources Inc

AGF Investments Trust AGF Global Infrastructure ETF

GLACIER LAKE RESORCES by Glacier Lake Resources

Glacier Lake Resources Inc

VanEck India Growth Leaders ETF

Lithium Lion Metals Inc Ordinary Shares

PANTHER MINERALS INC by PANTHER MINERALS INC.

Panther Minerals Inc

GRAYSCALE LIVEPEER TR by Grayscale Livepeer Trust (LPT)

Cleantek Industries Inc

GREAT LAKES GRAPHITE INC by Great Lakes Graphite, Inc.

Great Lakes Graphite Inc

ProShares UltraShort Gold

GLOBAL DINING INC ORD by Global Dining, Inc.

Global-Dining Inc

GOLDLION HOLDING LTD by Goldlion Holdings Ltd.

Goldlion Holdings Ltd

GLOBALINK INVESTMENT INC by Globalink Investment Inc.

Globalink Investment Inc

GLOBALINK INVT INC RT

Globalink Investment Inc Units (1 Ord, 1 Rts & 1 War)

Globalink Investment Inc Warrants(01/01/9999)

GLACIAL LAKE COM/CAP UNIT by Glacial Lakes Corn Processors Unit

Glacial Lakes Corn Processors Inc

Galenica Ltd

Golem - United States Dollar

Galmed Pharmaceuticals Ltd. - Ordinary Shares

Galmed Pharmaceuticals Ltd

Glacier Media Inc

Moonbeam - United States Dollar

Golar LNG Ltd

GRAYSCALE CHAINLINK TR by Grayscale Chainlink Trust (LINK)

Galan Lithium Ltd

GOLDEN STAR RES CORP by Golden Star Resource Corp

Golden Star Resources Corp

GLENVILLE BK HLDG CO INC by Glenville Bank Holding Co., Inc.

Glenville Bank Holding Co Inc

Clough Global Opportunities Fund Common Stock

Clough Global Opportunities Fund

Globant SA

GLOMAC BHD by Glomac Berhad

iShares Global Equity Factor ETF

CONTOURGLOBAL PLC by ContourGlobal PLC

Glow Holdings Inc

GasLog Partners LP 8.625% Series A Cumulative Redeemable Perpetual Fixed to Floating Rate Preference Units

GasLog Partners LP

GasLog Partners LP 8.200% Series B Cumulative Redeemable Perpetual Fixed to Floating Rate Preference Units

GasLog Partners LP 8.500% Series C Cumulative Redeemable Perpetual Fixed to Floating Rate Preference Units

JP Morgan analyst Reginald L. Smith <a target="_blank" href="https://www.benzinga.com/quote/SHOP/analyst-ratings" rel="noreferrer noopener">maintained an Overweight</a> rating on Shopify Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) after the company released its quarterly print Tuesday.
<a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43622684/shopify-q4-earnings-31-revenue-surge-free-cash-flow-growth-gmv-hits-94-5-billion" rel="noreferrer noopener">Fourth-quarter revenue</a> increased 31% versus Smith&#8217;s 26% and the Street&#8217;s 27% estimates, driven by a 7 pt acceleration in Merchant Solutions (primarily payments) revenue.
Gross margin contracted ~150bps from the prior year to 48.1%, a touch below Smith and the Street estimates (impacted by PayPal Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pypl#NASDAQ">PYPL</a>) revenue recognition change).
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/25/02/43608591/taiwan-semiconductors-trillion-dollar-valuation-the-chipmaker-enabling-ai-boom" rel="noreferrer noopener">Taiwan Semiconductor&#8217;s Trillion-Dollar Valuation: The Chipmaker Enabling AI Boom</a>
GAAP operating expenses increased 15% to $887 million (32% of revenue), consistent with Smith and Street expectations of $879 million and $895 million and prior guidance (32%-33% of revenue).
The free cash flow margin of 21.7% was ~170bps ahead of Smith and Street&#8217;s guidance of 21%.
GMV increased 26%, consistent with a broader acceleration in payment volume. Total MRR of $178 million came below Smith and the Street&#8217;s $181 million and $182 million.
The attach rate was 2.98%, up 13bps, and ahead of Smith&#8217;s 2.91% and Street&#8217;s 2.94% estimates. The first-quarter guidance was solid but insufficient to support the current valuation.
Shopify guided to mid-20% revenue growth compared to Smith and Street&#8217;s 25% and low-20% gross profit growth versus Smith&#8217;s 24% and Street&#8217;s 23%.
That said, the guidance calls for low double-digit operating expense growth (about consistent with recent trends) and mid-teens free cash flow margin against Smith and Street&#8217;s 18%, which was towards the low end of investor expectations of ~20%.
Ultimately, guidance points to stability next quarter, which is reasonable considering Shopify delivers premium growth and solid profitability. However, Smith noted the expectations were for further free cash flow margin expansion or more substantial gross profit growth to justify the investment in operating expenses.&nbsp;&nbsp;
SHOP Price Action:&nbsp;Shopify stock is up 2.41% at $122.79 at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43603073/mobileye-gains-analyst-upgrade-on-2025-catalysts-but-profit-delays-and-competition-keep-rating-neutral" target="_blank" rel="noreferrer noopener">Mobileye Gains Analyst Upgrade On 2025 Catalysts, But Profit Delays And Competition Keep Rating Neutral</a></li>
</ul>
Photo via Shutterstock

Analyst Color

News

Reiteration

Analyst Ratings

Tech

Trading Ideas

PYPL

SHOP

Shopify's Revenue Growth Outpaces Estimates, But PayPal-Related Margin Impact Raises Questions: Analyst

CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects 94 cents in EPS and $97.20 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=CVS" target="_blank" rel="noreferrer noopener"> before market hours</a>.
The stock is down 29.78% over the past year, up 22.72% YTD.
Let&#8217;s look at what the charts indicate for CVS stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/25/02/43458526/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-delivering-high-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields</a>
<h2 class="wp-block-heading">CVS Stock Chart Bullish Ahead Of Q4 Earnings</h2>
CVS stock&#8217;s current trend shows a strong bullish outlook, with the stock price trading above its five, 20, and 50-day exponential moving averages. This indicates buying pressure, which is a positive signal for future bullish movements.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11124038/Screenshot-2025-02-11-at-11.10.26-PM.png" alt="" class="wp-image-777081" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11124038/Screenshot-2025-02-11-at-11.10.26-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11124038/Screenshot-2025-02-11-at-11.10.26-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
However, technical signals present a mixed picture. CVS stock, at $54.34, trades below the eight-day simple moving average (SMA) of $55.17, signaling a bearish trend in the short term. Similarly, the 20-day SMA of $54.54 also signals a bearish stance, although this one is at a narrow margin.
On the positive side, the stock is above its 50-day SMA of $51.58, which is a bullish indicator. The Moving Average Convergence Divergence (MACD) is currently at 1.18, reinforcing a bullish sentiment. Furthermore, CVS Health&#8217;s Relative Strength Index (RSI) stands at 55.03, indicating that the stock is neither overbought nor oversold, leaving room for potential upward movement. 
However, the stock price remains below its 200-day SMA of $56.98, which introduces some resistance. 
Overall, while CVS Health has strong bullish signals in the short and medium term, resistance from longer-term averages may limit the upside until the stock decisively clears these levels. Investors should be mindful of the mixed signals and monitor for a break above key resistance points.
<h2 class="wp-block-heading">CVS Analysts See 17% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/CVS/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on CVS stock stands at a Buy currently with a price target of $78.63. Analysts from Evercore ISI Group, Truist Securities and Deutsche Bank recently released ratings for CVS stock, with an average price target of $63.67. This suggests a potential 17% upside for the stock.
CVS Stock Price Action: CVS stock was trading 0.11% lower at $54.25 at the time of publication Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/insights/government/25/02/43496836/this-house-of-representative-just-sold-up-to-50k-in-cvs-health-stock">This House of Representative Just Sold Up To $50K In CVS Health Stock</a></li>
</ul>
Photo: Shutterstock

Health Care

Technicals

Previews

General

CVS Stock Approaches Q4 Earnings With Resistance In Sight

Senseonics Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SENS#NYSE">SENS</a>) short percent of float has risen 13.15% since its last report. The company recently reported that it has 48.76 million shares sold short, which is 8.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Senseonics Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739301322_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Senseonics Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Senseonics Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Senseonics Holdings's peer group average for short interest as a percentage of float is 5.65%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

SENS

Peering Into Senseonics Holdings's Recent Short Interest

It's a battle of the stocks as Kraft Heinz Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NYSE">KHC</a>) and Restaurant Brands International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) prepare to release their <a href="https://www.benzinga.com/earnings">fourth-quarter earnings on Wednesday</a>.
The technical indicators paint two very different pictures for these stocks, and both face crucial resistance levels as they approach their earnings reports.
<h2 class="wp-block-heading">Kraft Heinz: Battling Bears &amp; Resistance</h2>
KHC stock has had a rough ride, down 19.09% over the past year and 4.39% year-to-date. Trading at $29.43, the stock is below its five, 20, and 50-day exponential moving averages, signaling a strong bearish trend. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11131044/Screenshot-2025-02-11-at-11.28.23-PM.png" alt="" class="wp-image-777117" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11131044/Screenshot-2025-02-11-at-11.28.23-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11131044/Screenshot-2025-02-11-at-11.28.23-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The eight-day and 20-day simple moving averages (SMAs) are at $29.14 and $29.27, respectively, with the stock trading above them, suggesting short-term strength. 
However, the stock's MACD (moving average convergence/divergence) of a negative 0.28 indicates bearish sentiment. KHC stock also trades below its 50-day SMA of $30.15 and its 200-day SMA of $33.34, with its RSI (relative strength index) of 48.56 hints at neutral conditions. 
Any dip in RSI from here towards oversold conditions under 30, could set the stage for a possible rebound if earnings surprise positively.
Wall Street expects fourth-quarter earnings of 78 cents per share and $6.67 billion in revenue, per <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1">Benzinga Pro</a> data.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43474912/coffee-prices-soar-over-100-near-historic-rally-as-inflation-percolates-through-supply-chain">Coffee Prices Soar Over 100%, Near Historic Rally As Inflation Percolates Through Supply Chain</a>
<h2 class="wp-block-heading">Restaurant Brands: Riding The Bullish Wave</h2>
Restaurant Brands, the parent company of Tim Hortons and Burger King, is enjoying a more bullish outlook. Trading at $66.13, QSR stock is above its five, 20, and 50-day exponential moving averages, indicating strong buying pressure.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11131054/Screenshot-2025-02-11-at-11.28.33-PM.png" alt="" class="wp-image-777118" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11131054/Screenshot-2025-02-11-at-11.28.33-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11131054/Screenshot-2025-02-11-at-11.28.33-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The eight-day SMA of $63.58 and 20-day SMA of $62.25 signal further upward momentum, although the 200-day SMA at $69.00 presents resistance. 
With an RSI of 66.44, QSR is nearing overbought levels, signaling caution. 
Wall Street expects fourth-quarter earnings of 79 cents per share and $2.27 billion in revenue, per <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1">Benzinga Pro</a> data.
<h2 class="wp-block-heading">Investor Takeaways</h2>
Kraft Heinz faces a fight against bearish trends, but a strong earnings report could spark a rebound. 
Restaurant Brands is riding high but may hit resistance—investors should watch for signs of a pullback before jumping in.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/02/43616252/bill-ackman-calls-out-coca-cola-pepsi-over-obesity-crisis-ross-gerber-notes-he-owns-several-crap-food-companies">Bill Ackman Calls Out Coca-Cola, Pepsi Over Obesity Crisis — Ross Gerber Notes &#8216;He Owns Several Crap Food Companies&#8217;</a></li>
</ul>
Image: Shutterstock

Restaurants

Kraft Heinz Vs. Restaurant Brands: The Technical Showdown Ahead Of Q4 Earnings

UiPath's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) short percent of float has risen 10.66% since its last report. The company recently reported that it has 32.51 million shares sold short, which is 7.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.77 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>UiPath Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739301317_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UiPath has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing UiPath's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UiPath's peer group average for short interest as a percentage of float is 5.00%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

PATH

Looking Into UiPath's Recent Short Interest

DOCS

CORRECTION: Doximity Ticker Is 'DOCS'

Treasure Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NYSE">TGL</a>) short percent of float has risen 65.79% since its last report. The company recently reported that it has 185 thousand shares sold short, which is 0.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Treasure Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739301312_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Treasure Global has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Treasure Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Treasure Global's peer group average for short interest as a percentage of float is 7.07%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Treasure Global?

WIIM

Doximity shares are trading lower. The stock may be pulling back following recent strength.

ARWR

Arrowhead Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results.

On Monday, Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)&nbsp;and Astellas Pharma Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMF#OTC">ALPMF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALPMY#OTC">ALPMY</a>) released additional follow-up results from the Phase 3 EV-302 trial (also known as KEYNOTE-A39) of Padcev&nbsp;(enfortumab vedotin) plus Keytruda (pembrolizumab) in patients with previously untreated locally advanced or metastatic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43610057/pfizer-and-astellas-padcev-enfortumab-vedotin-ejfv-plus-keytruda-pembrolizumab-shows-long-term-eff" rel="noreferrer noopener">urothelial cancer (la/mUC)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43463168/pfizer-q4-earnings-revenue-and-eps-beat-seagen-and-covid-19-products-show-strength-issues-strong-fy25-outlook" rel="noreferrer noopener">Pfizer Q4 Earnings: Revenue And EPS Beat, Seagen And COVID-19 Products Show Strength, Issues Strong FY25 Outlook</a>
The results showed a sustained overall survival (OS) and progression-free survival (PFS) benefit consistent with the findings of the primary analysis after an additional 12 months of follow-up (median follow-up of 29.1 months).
<ul>
<li>Results showed enfortumab vedotin plus pembrolizumab reduced the risk of death by 49% versus chemotherapy.</li>
<li>The median OS was 33.8 months for the combination versus 15.9 months for chemotherapy.</li>
<li>The OS benefit was observed in all prespecified subgroups, including cisplatin eligible and ineligible subgroups.</li>
<li>Enfortumab vedotin plus pembrolizumab also reduced the risk of disease progression or death by 52% versus chemotherapy.</li>
<li>The median PFS was 12.5 months for the combination versus 6.3 months for chemotherapy.</li>
<li>The safety profile was consistent with previous findings and no new safety concerns were identified.</li>
</ul>
In addition to longer follow-up data, an exploratory analysis evaluating treatment outcomes and safety profile in patients with confirmed complete response (cCR) will also be presented.
<ul>
<li>Among patients evaluable for response, a confirmed objective response rate (cORR) was 67.5% for enfortumab vedotin plus pembrolizumab compared to 44.2% for chemotherapy.</li>
<li>Median duration of response (DOR) was 23.3 months for the combination and 7.0 months for chemotherapy.</li>
<li>A cCR was achieved in 30.4% of patients treated with enfortumab vedotin plus pembrolizumab and 14.5% of patients treated with chemotherapy.</li>
<li>The median duration of cCR was not reached for the combination and 15.2 months for chemotherapy.</li>
<li>In patients with cCR, grade ≥3 treatment-related adverse events occurred in 61.7% of patients in the enfortumab vedotin plus pembrolizumab arm compared to 71.9% in the chemotherapy arm. There were no treatment-related deaths in the cCR subgroup.</li>
</ul>
Price Action: PFE stock is down 1.29% at $25.54 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43629316/marriott-tops-q4-estimates-as-2025-outlook-pressures-stock" target="_blank" rel="noreferrer noopener">Marriott Tops Q4 Estimates As 2025 Outlook Pressures Stock</a></li>
</ul>
Image via Shutterstock

Biotech

Large Cap

ALPMF

ALPMY

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

SMCI

Super Micro Computer shares are trading lower amid volatility ahed of the company's Q1 earnings report.

Trading in Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) <a href="https://www.benzinga.com/news/offerings/25/02/43593686/whats-going-on-with-snap-stock-monday-2">is quiet Tuesday</a>. The shares have been holding above-important support around $10.40. But there is a good chance the support breaks and the price falls.
The company&#8217;s stock chart shows some characteristics of a classic ‘Head &amp; Shoulders Pattern'. This is why our team of technical analysts has made Snap our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
Many analysts don't understand the fundamentals and basics of technical analysis. They try to identify patterns on charts without understanding the price action that causes them to form.
It's rare to see a precise or ‘textbook' pattern on a chart. But that isn't important. What is, is that an analyst understands price action and psychology that is occurring.
A Head and Shoulders is a ‘reversal pattern'. This means at has to occur and the end of an uptrend. It shows the bears are taking the leadership from the bulls.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/02/43623639/coca-cola-pops-in-q4-revenue-soars-6-ceo-hails-all-weather-strategy">Coca-Cola Pops In Q4—Revenue Soars 6%, CEO Hails &#8216;All-Weather Strategy&#8217;</a>
One thing that happens when the bears are taking over is that ‘lower highs' form. Markets don't go in straight lines. They go in peaks and valleys. When a peak forms at a lower price level than the previous peak did, traders say it is a lower high.
This means that as time passes, sellers are willing to come into the market at lower levels. This is why the ‘right shoulder' forms at a lower price than the ‘head' does in a Head &amp; Shoulders.
As you can see on the chart below, Snap&#8217;s last two peaks occurred at lower levels than the peak that would be considered the Head did in December. This shows that since then, people who want to sell are getting anxious and are willing to accept less for their shares.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="552" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11140021/115-1024x552.png" alt="" class="wp-image-777202" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11140021/115-1024x552.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11140021/115-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11140021/115-768x414.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11140021/115.png 1522w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Now the stock is testing support around the $10.40 level. Because sellers have become increasingly aggressive while the buyers have been willing to be patient and hang out around the support level mean there is a good chance it breaks.
Aggressive sellers and patient buyers is typically bearish for a market.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43632327/steel-stocks-breakout-analyst-sees-bullish-setup-for-us-steel-nucor-steel-dynamics">Tariffs Drive Steel Stock Gains As Analyst Highlights Catalysts For Nucor, US Steel</a></li>
</ul>
Image: Shutterstock

SNAP

Stock Of The Day: Does Classic Head & Shoulders Pattern Mean Snap Goes Lower?

<a href="https://www.semafor.com/article/02/11/2025/trump-moves-to-significantly-reduce-federal-workforce" title="https://www.semafor.com/article/02/11/2025/trump-moves-to-significantly-reduce-federal-workforce">https://www.semafor.com/article/02/11/2025/trump-moves-to-significantly-reduce-federal-workforce</a>

'Trump Moves To 'Significantly' Reduce Federal Workforce'

Five former treasury secretaries are taking aim at the Department of Government Efficiency and Elon Musk for alleged overreach and abuse of powers by the new <a href="https://www.benzinga.com/news/25/02/43617113/bill-gates-challenges-elon-musk-led-doge-approach-to-shutting-down-usaid-asks-if-it-fits-american-value-system">White House administration.</a>
What Happened: Musk has been <a href="https://www.benzinga.com/25/02/43452103/elon-musk-appointed-as-special-government-employee-amid-doge-department-push-cant-do-anything-without-our-approval-says-trump">put in charge of leading</a> the Department of Government Efficiency by President Donald Trump.
In the role, Musk has promised <a href="https://www.benzinga.com/news/25/02/43426165/elon-musks-daily-4-billion-doge-target-will-lead-to-30-cut-in-federal-spending-says-economist-jason-furman">to find billions</a> to trillions of dollars in savings for U.S. taxpayers. The billionaire has been granted access to many parts of the government, leading to pressure from the public and some members of Congress on alleged overreach.
Five former treasury secretaries believe Musk's actions could bring harm to the country's payments system.
Here are the five former treasury secretaries who co-authored a new<a href="https://www.nytimes.com/2025/02/10/opinion/treasure-secretaries-doge-musk.html"> op-ed</a> in the New York Times and their years of service in the role:
<ul>
<li>Robert Rubin: 1995 to 1999 (Bill Clinton)</li>
<li>Lawrence Summers: 1999 to 2001 (Bill Clinton)</li>
<li>Timothy Geithner: 2009 to 2013 (Barack Obama)</li>
<li>Jacob Lew: 2013 to 2017 (Barack Obama)</li>
<li>Janet Yellen: 2021 to 2025 (Joe Biden)</li>
</ul>
"Our roles were multifaceted. We sought to develop sound policy to advance the president's agenda and represent the economic interests of the United States on the world stage. But in doing that, we recognized that our most fundamental responsibility was the faithful execution of the laws and Constitution of the United States," the former secretaries said.
The five said that they are "fortunate" that there were no unlawful attempts to "undermine the nation's financial commitments" during their time in office.
"Regrettably, recent reporting gives substantial cause for concern that such efforts are underway today."
The former treasury secretaries say the nation's payment system is operated by a small group of nonpartisan civil servants, a position that they allege has been compromised by the political actors of the "so-called Department of Government Efficiency."
The op-ed alleges that the political actors have not gone through the same ethics rules as civil servants and have potential financial conflicts of interest in their roles.
"They lack training and experience to handle private, personal data – like Social Security numbers and bank account information. Their power subjects America's payments system and the highly sensitive data within it to the risk of exposure, potentially to our adversaries."
The former treasury secretaries write that the legislative branch has the "sole authority" to pass laws concerning how and where federal dollars are spent. The Treasury Department is not supposed to make determinations about which promises it will keep of the laws passed by Congress. The op-ed cites quotes from Supreme Court justices who agreed with this logic previously.
The op-ed said the Supreme Court ruled unanimously that the president does not have the power to withhold federal funds that Congress authorized previously when a similar challenge was made by the Richard Nixon administration.
"We take the extraordinary step of writing this piece because we are alarmed about the risks of arbitrary and capricious political control of federal payments, which would be unlawful and corrosive to our democracy."
Among the federal funds that have been authorized by Congress include Social Security checks, Veterans benefit checks, Medicare reimbursements, Federal worker payments and payments for members of the military.
"People often rely on these funds for survival, making any risk of their cutoff or delay existential."
Check This Out:
<ul>
<li><a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent021125">Lawmakers Are Making Huge Investments In 2025. See What They&#8217;re Buying And Selling With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: The op-ed stated that current Treasury Secretary Scott Bessent confirmed no federal payment blocks have occurred yet.
"We hope this commitment stands. It is how the framers intended it when they designed a government with checks and balances that gave the executive branch a host of powers, but provided for elected members of Congress, and Congress alone, the authority to levy taxes and spend federal funds," the former treasury secretaries wrote.
In a <a href="https://x.com/LHSummers/status/1888923226585113038">tweet</a>, Summers said the guest essay was made due to being alarmed about the risk of political control of federal payments. The tweet prompted a response from Musk.
"Listen Larry, we need to stop government spending like a drunken sailor on fraud &amp; waste or America is gonna go bankrupt. That does mean a lot of grifters will lose their grift and complain loudly about it. Too bad. Deal with it," Musk <a href="https://x.com/elonmusk/status/1888998928781025534">tweeted</a>.
Summers <a href="https://x.com/LHSummers/status/1889022586366943313">acknowledged </a>that Musk is right to be focused on stopping fraud and grift, but said he hopes the Treasury Department and DOGE comply with the law and offered to work with the billionaire.
On Tuesday morning, Trump posted a message on his Truth Social platform saying billions of dollars of fraud, waste and abuse have already been found while investigating the "incompetently run Government."
"Now certain activists and highly political judges want us to slow down, or stop. Losing this momentum will be very detrimental to finding the TRUTH, which is turning out to be a disaster for those involved in running our Government. Much left to find." Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/113985325416343873">said</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43429913/larry-summers-slams-trumps-bizarre-tariffs-on-canada-and-mexico-this-is-a-stop-or-ill-shoot-myself-in-the-foot-kind-of-policy">Larry Summers Slams Trump&#8217;s &#8216;Bizarre&#8217; Tariffs On Canada And Mexico: &#8216;This Is A Stop-Or-I&#8217;ll-Shoot-Myself-In-The-Foot Kind Of Policy&#8217;</a></li>
</ul>
Image created using photos from Shutterstock.

Politics

Musk's DOGE Is Attack On Democracy: Yellen, Rubin, 3 More Ex-Treasury Chiefs

4 analysts have shared their evaluations of Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $85.25, a high estimate of $95.00, and a low estimate of $74.00. Observing a downward trend, the current average is 15.8% lower than the prior average price target of $101.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1739300466_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Bunge Global among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$74.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bunge Global. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Bunge Global compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Bunge Global's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Bunge Global's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bunge Global analyst ratings.</a>
<h2>Get to Know Bunge Global Better</h2>
Bunge Global SA formerly Bunge Ltd is an agribusiness and food company with operations along the farm-to-consumer food chain. The company segments include Agribusiness; Refined and Specialty Oils; Milling; Sugar and Bioenergy and Corporate and Other. It generates maximum revenue from the Agribusiness segment. The company is an oilseed processor and producer of vegetable oils and protein meals, based on processing capacity, a grain processor, the seller of packaged plant-based oils, producer and seller of wheat flour, bakery mixes, and corn-based products in North and South America.
<h3>Bunge Global: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Negative Revenue Trend: Examining Bunge Global's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -9.27% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Bunge Global's net margin excels beyond industry benchmarks, reaching 1.71%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bunge Global's ROE stands out, surpassing industry averages. With an impressive ROE of 2.2%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.89%, the company showcases effective utilization of assets.
Debt Management: Bunge Global's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.7.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess Bunge Global: What You Need To Know

In the latest quarter, 4 analysts provided ratings for Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $20.5, a high estimate of $25.00, and a low estimate of $17.00. A 8.89% drop is evident in the current average compared to the previous average price target of $22.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1739300453_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Progyny's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Cherny</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Progyny. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Progyny compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Progyny's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Progyny's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PGNY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Progyny analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Progyny Better</h2>
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
<h3>Financial Insights: Progyny</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Progyny's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 2.04%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Progyny's net margin is impressive, surpassing industry averages. With a net margin of 3.64%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Progyny's ROE excels beyond industry benchmarks, reaching 2.34%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Progyny's ROA stands out, surpassing industry averages. With an impressive ROA of 1.53%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Progyny's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PGNY

Breaking Down Progyny: 4 Analysts Share Their Views

In the preceding three months, 5 analysts have released ratings for Harmony Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $66.4, a high estimate of $75.00, and a low estimate of $52.00. Observing a downward trend, the current average is 1.38% lower than the prior average price target of $67.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1739300442_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Harmony Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Hoang</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$75.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Harmony Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Harmony Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Harmony Biosciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HRMY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Harmony Biosciences analyst ratings.</a>
<h2>Discovering Harmony Biosciences: A Closer Look</h2>
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
<h3>Harmony Biosciences: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Harmony Biosciences showcased positive performance, achieving a revenue growth rate of 16.08% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Harmony Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.78%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Harmony Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.12% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Harmony Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.16% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Harmony Biosciences's debt-to-equity ratio is below the industry average at 0.31, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HRMY

Demystifying Harmony Biosciences: Insights From 5 Analyst Reviews

In the latest quarter, 7 analysts provided ratings for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Alnylam Pharmaceuticals and provided 12-month price targets. The average target is $332.29, accompanied by a high estimate of $400.00 and a low estimate of $296.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.17%. 
<img src="https://www.benzinga.com/files/images/story/2025/1739300431_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Alnylam Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$314.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$296.00</td>
<td>$296.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Alnylam Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Alnylam Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Alnylam Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Alnylam Pharmaceuticals</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Alnylam Pharmaceuticals's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -33.26%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -22.27%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -761.91%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.72%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Alnylam Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 40.24. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNY

Breaking Down Alnylam Pharmaceuticals: 7 Analysts Share Their Views

Ratings for Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Insmed, revealing an average target of $92.6, a high estimate of $101.00, and a low estimate of $83.00. Surpassing the previous average price target of $85.00, the current average has increased by 8.94%.
<img src="https://www.benzinga.com/files/images/story/2025/1739300419_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Insmed. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$74.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Insmed. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Insmed's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insmed analyst ratings.</a>
<h2>Unveiling the Story Behind Insmed</h2>
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
<h3>Unraveling the Financial Story of Insmed</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Insmed's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 18.15%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -236.04%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Insmed's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -84.45%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Insmed's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.42%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Insmed's debt-to-equity ratio is below the industry average. With a ratio of 2.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INSM

Insmed Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Across the recent three months, 7 analysts have shared their insights on Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Arch Capital Group, revealing an average target of $114.71, a high estimate of $136.00, and a low estimate of $100.00. This current average represents a 5.09% decrease from the previous average price target of $120.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1739300410_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Arch Capital Group by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Carletti</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$121.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$106.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$109.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Jay Cohen</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$136.00</td>
<td>$143.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Arch Capital Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Arch Capital Group compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Arch Capital Group's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Arch Capital Group's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ACGL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Arch Capital Group analyst ratings.</a>
<h2>Delving into Arch Capital Group's Background</h2>
Arch Capital Group Ltd is a Bermuda company which writes insurance and reinsurance with operations in Bermuda, the United States, Canada, Europe, Australia and United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage two operating segments: corporate and other. The insurance segment provides specialty risk solutions to client across a variety of industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
<h3>Breaking Down Arch Capital Group's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Arch Capital Group's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 36.05%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Arch Capital Group's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.83%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Arch Capital Group's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.74%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Arch Capital Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.41%, the company showcases efficient use of assets and strong financial health.
Debt Management: Arch Capital Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.13.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Globe Life

ニュース

最新ニュース Globe Life (NYSE:GL) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル